Last reviewed · How we verify
BCD-063
BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.
BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. Used for Psoriasis, Psoriatic arthritis.
At a glance
| Generic name | BCD-063 |
|---|---|
| Also known as | glatiramer acetate |
| Sponsor | Biocad |
| Drug class | IL-17A inhibitor monoclonal antibody |
| Target | IL-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
BCD-063 targets interleukin-17A (IL-17A), a key cytokine in the IL-17 signaling pathway that drives inflammation in autoimmune conditions. By neutralizing IL-17A, the drug reduces inflammatory responses and immune cell activation. This mechanism is particularly relevant for conditions characterized by Th17-mediated inflammation, such as psoriasis and other autoimmune disorders.
Approved indications
- Psoriasis
- Psoriatic arthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |